The Nasdaq closed below its Aug. 4 follow-through day low, a highly bearish signal for the market rally. Walmart, SpaceX, CrowdStrike were big losers.

Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 14.69% in the second quarter of 2026, slightly trailing the 15.20% gain of the S&P 500 Index as market performance remained highly concentrated in artificial intelligence (AI)-related […]

Guardant Health (NASDAQ:GH) highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments,

TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.

Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.

Guardant Health (GH) just reported its second quarter 2026 results, with sales of US$334.98 million and a net loss of US$120.14 million, and simultaneously raised its full year 2026 revenue guidance. See our latest analysis for Guardant Health. Guardant Health’s latest earnings release, stronger revenue guidance for 2026 and the recent shelf registration filing come after a powerful run in the stock, with a 90 day share price return of 67.66% and a 1 year total shareholder return of 199.62%...

Shield screening volumes more than doubled, with UnitedHealth coverage now active.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Dow Jones AI giant Microsoft stock is breaking out past a buy point following last week's earnings-fueled surge that saw the stock rally 21%.

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 44.3% year on year to $335 million. The company’s full-year revenue guidance of $1.35 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP loss of $0.42 per share was 7.8% below analysts’ consensus estimates.

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.

July was a dreadful month for growth stocks and indexes, with things like the IBD 50 Index and the iShares MSCI USA Momentum Fund (MTUM) off well over 10%. But I still like Guardant Health Inc. (GH), which has only retreated to its 50-day line on modest volume, notes Mike Cintolo, editor of Cabot Growth Investor.

GE Aerospace and NetApp, whose enterprise data storage has made it an AI infrastructure play, lead this weekend's list of five stocks near buy points, which are showing relative strength in a tricky market. Joining GE and NTAP is oncology diagnostics firm Guardant Health. Guardant Health is part of the IBD Leaderboard portfolio of elite stocks and Viking is on the watchlist for possible inclusion.

Guardant Health (NASDAQ:GH) reported second-quarter 2026 revenue of $335 million, up 44% from a year earlier, as growth accelerated across its oncology, biopharma and data, and screening businesses. The company also raised its full-year revenue outlook, citing demand for its Guardant360 and Shield o

Moby summary of Guardant Health, Inc.'s Q2 2026 earnings call

Guardant Health Inc (GH) raises full-year guidance to $1.34-$1.36 billion as Shield volumes triple and Guardant360 Liquid CDx gains FDA approval, despite widening EBITDA losses.

Guardant Health reported past second-quarter 2026 results showing sales of US$334.98 million versus US$232.09 million a year earlier, alongside a wider net loss of US$120.14 million and loss per share of US$0.90. While revenue expanded sharply over both the quarter and first half of 2026, higher losses highlight the tension between growth investment and Guardant Health’s profitability ambitions. We’ll now examine how this strong top-line expansion, set against continued net losses, affects...

Guardant Health (GH) delivered earnings and revenue surprises of -5.00% and +6.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 44.3% year on year to $335 million. The company’s full-year revenue guidance of $1.35 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP loss of $0.42 per share was 7.8% below analysts’ consensus estimates.

Guardant Health is the IBD Stock Of The Day in a thriving market for colon cancer screening tests. GH stock popped nearly 7% in extended Thursday trading. Health and biotech stocks are acting well in the current market.

Stock Market Today: The Dow Jones index rallies with the Nasdaq composite following a Fed Day tumble. Meta stock plunges on earnings.

Diagnostics company Guardant Health (NASDAQ:GH) will be announcing earnings results this Thursday after market close. Here’s what to look for.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Guardant Health (GH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Abbott will market Freenome’s SimpleScreen CRC test in the U.S., alongside its Cologuard stool test. SimpleScreen will compete with Guardant Health’s Shield blood test for colorectal cancer screening.

Apple stock is holding up the best out of the Magnificent Seven stocks as the company has proceeded cautiously with its AI investments.

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States […]

If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.